J
Joel S. Finkelstein
Researcher at Sunnybrook Health Sciences Centre
Publications - 303
Citations - 23338
Joel S. Finkelstein is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Osteoporosis & Bone density. The author has an hindex of 75, co-authored 282 publications receiving 21346 citations. Previous affiliations of Joel S. Finkelstein include Sunnybrook Research Institute & Women's College, Kolkata.
Papers
More filters
Journal ArticleDOI
Hypovitaminosis D in Medical Inpatients
Melissa K. Thomas,Donald M. Lloyd-Jones,Ravi Thadhani,Albert C. Shaw,Donald J. Deraska,Barrett T. Kitch,Eleftherios C. Vamvakas,Ian M. Dick,Richard L. Prince,Joel S. Finkelstein +9 more
TL;DR: Hypovitaminosis D is common in general medical inpatients, including those with vitamin D intakes exceeding the recommended daily allowance and those without apparent risk factors for vitamin D deficiency.
Journal ArticleDOI
The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis
TL;DR: Alendronate impairs the ability of parathyroid hormone to increase the bone mineral density at the lumbar spine and the femoral neck in men.
Journal ArticleDOI
Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism
Laurence Katznelson,Joel S. Finkelstein,David A. Schoenfeld,Daniel I. Rosenthal,Ellen J. Anderson,Anne Klibanski +5 more
TL;DR: It is concluded that testosterone therapy given to adult men with acquired hypogonadism decreases sc fat and increases lean muscle mass and testosterone therapy reduces bone remodeling and increases trabecular bone density.
Journal ArticleDOI
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Matthew R. Smith,Francis J. McGovern,Anthony L. Zietman,Mary Anne Fallon,Douglas Hayden,David A. Schoenfeld,Philip W. Kantoff,Joel S. Finkelstein +7 more
TL;DR: Pamidronate prevents bone loss in the hip and lumbar spine in men receiving treatment for prostate cancer with a gonadotropin-releasing hormone agonist.
Journal ArticleDOI
Changes in body composition during androgen deprivation therapy for prostate cancer.
Matthew R. Smith,Joel S. Finkelstein,Francis J. McGovern,Anthony L. Zietman,Mary Anne Fallon,David A. Schoenfeld,Philip W. Kantoff +6 more
TL;DR: GnRH agonists increase weight and percentage fat body mass and decrease percentage lean body mass, fat distribution, and muscle size in men with nonmetastatic prostate cancer.